



**Ref: BHL/ STEX 68/ 2025-26**  
**Date: March 17, 2026**

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001  <b>Scrip Code: 539872</b>	National Stock Exchange of India Limited 5 <sup>th</sup> Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051  <b>Symbol: BAJAJHCARE</b>
---	--

Dear Sir/Madam,

**Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Company has signed Deed of Assignment and Transfer with Bethany Pharmacare Private Limited on March 17, 2026 for the sale of an undertaking of the Company situated at Plot No. L-9/3, MIDC, Tarapur, Taluka Boisar, District Palghar, Maharashtra.

Further, we hereby confirm that none of the promoter/ promoter group/ group companies have any interest in the aforesaid entity and the transaction does not fall within the purview of related party transactions.

The brief details, in accordance with the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 are enclosed as “Annexure-I”.

You are requested to take the same on record.

Thanking You,

**For and on behalf of Bajaj Healthcare Limited**

**Monica Tanwar**  
**Company Secretary & Compliance Officer**

Encl: as above

**BAJAJ HEALTHCARE LIMITED**

**Registered Office:** 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane - 400604  
Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com  
CIN No. L99999MH1993PLC072892

**Annexure-I**

**Details required under the Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026**

<b>Sr. No</b>	<b>Particulars</b>	<b>Amount</b>
a)	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	The undertaking was not operational during the last financial year, therefore turnover or revenue contribution is Nil.
b)	Date on which the agreement for sale has been entered into	March 17, 2026
c)	The expected date of completion of sale/disposal	The transaction is expected to be completed upon fulfillment of conditions as mentioned under the Deed of Assignment and Transfer.
d)	Consideration received from such sale/disposal	The consideration will be Rs. 2.50 Crores (approx.).
e)	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	The Buyer is Bethany Pharmacare Private Limited which does not belong to the Promoter/Promoter Group/ group companies and the transaction does not fall under the ambit of the Related Party Transactions.
f)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	No
g)	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	The Company has taken prior approval of Shareholders of the Company on August 05, 2023 vide postal ballot notice dated June 28, 2023 and complied with regulation 37A of SEBI LODR Regulations.
h)	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable